Table 1.
Correlation of circ_0059707 expression with clinical characteristics in AML patients.
| Patient’s Parameters | Low (n = 62) | High (n = 32) | p Value |
|---|---|---|---|
| Sex, male/female | 37/25 | 19/13 | 0.847 |
| Age, median (range), years ∆ | 54 (15–81) | 59 (27–84) | 0.127 |
| WBC, median (range), ×109/L ∆ | 49.6 (0.8–528) | 55.8 (0.8–207.9) | 0.388 |
| Hemoglobin, median (range), g/L ∆ | 84.7 (42–138) | 93.3 (58–141) | 0.045 |
| Platelets, median (range), ×109/L ∆ | 46.6 (7–192) | 66.8 (5–382) | 0.103 |
| BM blasts, median (range), % ∆ | 46.1 (0–95.0) | 35.8 (0–80.0) | 0.050 |
| CR (+/−) | 27/22 | 8/13 | 0.297 |
| FAB classification | 0.433 | ||
| M0 | 1 | 0 | |
| M1 | 2 | 0 | |
| M2 | 24 | 17 | |
| M3 | 10 | 2 | |
| M4 | 14 | 5 | |
| M5 | 6 | 4 | |
| No data | 4 | 4 | |
| Risk classification | 0.273 | ||
| Low | 8 (13%) | 3 (9%) | |
| Intermediate | 37 (60%) | 23 (72%) | |
| High | 16 (26%) | 4 (13%) | |
| No data | 1 (2%) | 2 (6%) | |
| Karyotypes | 0.801 | ||
| normal | 29 (47%) | 17 (53%) | |
| t(8;21) | 5 (8%) | 2 (6%) | |
| t(16;16) | 1 (2%) | 0 (0%) | |
| t(15;17) | 10 (16%) | 2 (6%) | |
| t(9;22) | 1 (2%) | 0 (0%) | |
| +8 | 3 (5%) | 2 (6%) | |
| −7/7q- | 1 (2%) | 0 (0%) | |
| complex | 6 (10%) | 3 (9%) | |
| others | 5 (8%) | 4 (13%) | |
| No data | 1(2%) | 2 (6%) | |
| Gene mutations | |||
| CEBPA (+/−) | 3/49 | 2/23 | 0.361 |
| NPM1 (+/−) | 10/42 | 7/20 | 0.250 |
| FLT3-ITD (+/−) | 6/46 | 2/23 | 0.322 |
| c-KIT (+/−) | 2/50 | 1/24 | 0.494 |
| N/K-RAS (+/−) | 6/37 | 2/15 | 0.417 |
| IDH1/2 (+/−) | 2/41 | 1/16 | 0.431 |
| DNMT3A (+/−) | 4/48 | 2/23 | 0.486 |
| U2AF1 (+/−) | 0/43 | 0/17 | - |
| SRSF2 (+/−) | 0/43 | 1/16 | 0.060 |
| SETBP1 (+/−) | 1/34 | 0/16 | 0.263 |
| TP53 (+/−) | 1/12 | 1/8 | 0.420 |
| TET2 (+/−) | 0/8 | 1/4 | 0.134 |
Note: ∆ median (range).